Image via BioPharma Dive
Last updated
Eli Lilly and Company: Ma Activity
Eli Lilly acquired Curevo Vaccine, gaining access to next-generation shingles vaccine powered by AAHI's SLA-SE adjuvant technology. Technology represents significant advancement in robust T-cell immunity with favorable safety profile.
Source: BioPharma Dive
The leadership read
Consolidation of this kind shifts demand toward integration and transformation leadership bench strength in the sector.
Market context: This lands while the Talent Market Index reads 107 (Hot) — down 1.8 versus the prior month — and Oceania signal share is easing (-4.4pts).
Eli Lilly and Company: 3 signals in the last 90 days; 0.2% of MitchelLake's Americas signal flow; 4 tracked across 85 days.
Also at Eli Lilly and Company →
More signals across Oceania
Ma Activity · Oceania
Teva Pharmaceuticals →Active litigation against Eli Lilly with appeals court victory reviving lawsuit. Teva won the ability to challenge Lilly's FDA exclusivity extension that delayed its generic Forteo launch. Large-scale legal battle ongoing with significant business implications.
Ma Activity · Oceania
KKR →KKR confirmed participation in a consortium pursuing a $7.7 billion takeover bid for Steadfast at $6 per share.
Ma Activity · Oceania
Criteo →Vista Equity Partners and Quinti Capital have submitted acquisition bids for Criteo, a Nasdaq-listed company. The deal would likely result in delisting.
Ma Activity · Oceania
EQT →EQT agreed to acquire Orikan from Five V for $475 million, delivering at least 3x return to original investors
Ma Activity · Oceania
Future Fund →Future Fund consortium bidding for Ausgrid's $3 billion smart metering business (Plus ES) in final stages of acquisition process
Ma Activity · Oceania
CapitaLand →A New York-based financial firm is advancing acquisition talks for CapitaLand's Australian lending unit, with an Asia-Pacific leader from Singapore driving the process
Intelligence powered by Autonodal ↗